Summary

Roche Board Chair Severin Schwan warns of «tectonic shifts» in the pharmaceutical industry and a lack of urgency in Switzerland. The agreement with the US government protects pharmaceutical sales, but significantly burdens the diagnostics business through tariffs. Schwan calls for Switzerland to learn from the German model of immediate reimbursement after approval and criticizes the sluggish availability of new medicines in the country.

People

Topics

  • Medicine prices and regulation
  • Trade tariffs and international trade conflicts
  • Switzerland as a pharma location
  • Research and innovation
  • Generational change in family businesses

Clarus Lead

Roche warns of strategic risks for the Swiss pharmaceutical sector: an agreement with the US government protects medicine sales from tariffs, yet the lucrative diagnostics business (14 billion francs in revenue in 2025) suffers massively. Schwan condemns insufficient political sensitivity to the urgency—«tectonic shifts» require faster adjustments in regulation and research funding. Switzerland lags behind other countries: only half as many innovative medicines are available on the specialty list as in Germany, which offers a more attractive reimbursement model.

Detailed Summary

The US tariff agreement offers only partial security. While pharmaceutical products are protected, tariffs hit the diagnostics business hard—particularly absurd: Roche exports more diagnostics globally from US factories than it imports, but pays twice over through Chinese retaliatory tariffs. The Obama negotiations on medicine prices require price concessions based on purchasing power parity: where Italy has lower prices, the US accepts surcharges; in the wealthier Switzerland, it demands discounts. This could affect Swiss patients.

The central bottleneck is domestic: access to new medicines has worsened despite approvals. The German model—immediate reimbursement from day one, price negotiations afterward with payback option—works better. Parliament has approved this path, but implementation at the regulatory level is pending. Schwan praises the new Federal Council working group on pharmaceutical issues and signals constructiveness, but warns: the lack of sense of urgency is «dangerous» for a location whose competitiveness depends on cutting-edge research and international talent flow.

Key Messages

  • Double tariff burden: Roche pays as a net exporter in the diagnostics sector through US and Chinese tariffs, while the pharmaceutical agreement offers only partial security.

  • Price parities reduce margins: Purchasing power-adjusted US price laws lead to discounts in Switzerland and possibly higher patient copayments.

  • Regulatory delays cost patients: Only 50% of innovative medicines available in Germany are on Switzerland's specialty list; the German immediate reimbursement model should be Switzerland's template.

  • Research location at risk: More than half of Roche's researchers come from abroad; the planned 10-million Switzerland initiative could hinder talent flow.

  • Lacking political speed: Decisions about new factory construction are made years in advance; current announcements primarily concern the USA and China, not Switzerland.

Critical Questions

  1. Evidence gap: How does Roche quantify the concrete impacts of Chinese retaliatory tariffs on the diagnostics business? Which margin scenarios are used for the planned price concessions in the US—and what data are these based on?

  2. Conflicts of interest: To what extent does Schwan speak here as an advocate for the pharmaceutical industry association or as an independent board chair? Does Roche have a commercial interest in delaying price regulation in Switzerland?

  3. Causality of regulation–plant relocation: Does Schwan prove causally that sluggish Swiss approval procedures lead to plant relocations—or are other factors (wages, energy costs, global supply chains) primary?

  4. Alternative to cutting-edge research: Why not focus more on acquiring biotech innovations instead of internal research? What specifically argues against the Novartis model of specialization?

  5. Feasibility of the German model: Germany pays higher expenditures for immediate reimbursement—how does Switzerland plan to cover these costs without raising supplementary contributions?

  6. Family shareholding and stability myth: Does strong family majority ownership prevent or accelerate quick strategic adjustments—what empirical data exists?

  7. 10-million initiative–research risk: How many of the 50% foreign research employees work in key areas (oncology, diagnostics), and how long is the recruitment lead time from domestic versus foreign sources?

  8. Payback model–financial viability: How does Switzerland calculate the budget impact of paybacks under the German model—is there a risk that reimbursement refusals will increase?

Sources

Primary Source: Roche President Schwan on Medicine Prices: «A Lot Is at Stake» – NZZ, 07.03.2026

Verification Status: ✓ 07.03.2026

This text was created with the support of an AI model. Editorial Responsibility: clarus.news | Fact-Check: 07.03.2026